

#### DAFTAR PUSTAKA

- Amir dan Bahar, 2009. *Tuberkulosis Paru. In: Buku Ajar Ilmu Penyakit Dalam. Cet1. InternaPublising, Jakarta Pusat.*
- Brooks G.F., Butel J.S., Morse S.A., 2008. *Mikrobiologi Kedokteran. Penerbit Buku Kedokteran EGC, Jakarta.*
- Camirero, JA. 2006. Treatment of Multidrug-resistant Tuberculosis: Evidence and Controversies. *Int J Tuberc Lung Dis* 2006;10: 829-37.
- Centers for Disease Control and Prevention, 2003. *Treatment of Tuberculosis. Morbidity and Mortality Weekly Report. Vol.52. No. RR-11. Department of Health and Human Service, Atlanta.*
- Da Silva, P.E.A., Palomino, J. C., 2011. Molecular basis and mechanisms of drug resistance in *Mycobacterium tuberculosis*: classical and new drugs. *J Antimicrob Chemother.* 66: 1417 - 1430.
- Depkes, RI. 2003. *Pedoman Nasional Penanggulangan Tuberkulosis. Cetakan 8. Depkes RI, Jakarta.*
- Depkes, RI. 2006. *Pedoman Nasional Penanggulangan Tuberkulosis. Ed 2. Cetakan 1. Depkes RI, Jakarta.*
- Depkes, RI. 2011. *Pedoman Nasional Pengendalian Tuberkulosis. Ed 2. Cetakan 1. Depkes RI, Jakarta.*
- Farley, J.E., Ram, M., Pan, W., Waldman, S., Cassell, G.H., Chaisson, R.E., et al. 2011. Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. *PLoS ONE.* 6(7): e20436
- Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. 2006. Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 368:1575-80.
- Hafkin, J., Modongo, C., Newcomb, C., Lowenthal, E., MacGregor, R.R., Steenhoff, A.P., et al. 2013.

Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana. *Int J Tuberc Lung Dis.* 17(3):348-353

Higgins, J.P.T., Green S. 2008. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.0 [updated February 2008]. The Cochrane Collaboration.

Isaakidis, P., Paryani, R., Khan, S., Mansoor, H., Manglani, M., Valiyakath, A., et al. 2013. Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India. *PLoS ONE.* 8(7): e68869

Isaakidis, P., Casas, E.C., Das, M., Tseretopoulou, X., Ntzani, E.E., Ford, N. 2014. Treatment outcomes for multidrug-resistant tuberculosis adults and children co-infected with HIV: a systematic review and meta-analysis. Abstract no. A-641-0095-04900. Diakses di <http://pag.aids2014.org/abstracts.aspx?aid=4900>.

Johnston, J.C., Shahidi, N.C., Sadatsafavi, M., Fitzgerald, J.M. 2009. Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. *PLoS ONE.* 4(9): e6914

Jumiarti, A. 2007. *Kuman TBC Mematikan*. pp:5. Penerbit Buku Kedokteran EGC, Jakarta.

Kemenkes, RI. 2011. *Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral*. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Jakarta.

Kemenkes, RI. 2012. *Petunjuk teknis tata laksana klinis ko-infeksi TB-HIV*. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Jakarta.

Kemenkes, RI. 2013. *Pedoman nasional pelayanan kedokteran tata laksana Tuberkulosis*. Direktorat

Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Jakarta.

Kepmenkes RI No 364/MENKES/SK/V/2009 tentang PEDOMAN PENANGGULANGAN TUBERKULOSIS (TB)

Kumar, V., Abbas, A.K., Aster, J.C., 2014. *Robbins and Cotran pathologic basis of disease*. Edisi 9. Elsevier Saunders, Philadelphia.

Muchtar, A., 2006. Farmakologi Obat Antituberkulosis (OAT) Sekunder. *Jurnal Tuberkulosis Indonesia*. Vol.3: 23-39.

Murray, P.R., Rosenthal, K.S., Pfaller, M.A., 2013. *Medical Microbiology*. Edisi 7. Elsevier Saunders, Philadelphia.

Nathanson, E., Gupta, R., Huamani, P., et al. 2004. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. *Int J Tuberc Lung Dis*. 8:1382-4.

Oladimeji, O., Isaakidis, P., Obasanya, O. J., Eltayeb, O., Khogali, M., Van den Bergh, R., et al. 2014. Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria. *PLoS ONE*. 9(4): e94393

Palacios, E., Franke, M., Muñoz, M., Hurtado, R., Dallman, R., Chalco, K., et al. 2012. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. *Int J Tuberc Lung Dis*. 16(3):348-354

Park, M.M., Davis, A.L., Schluger, N.W., Cohen, H., Rom, W.N. 1996. Outcome of MDR-TB Patients, 1983-1993: Prolonged Survival with Appropriate Therapy. *Am J Respir Crit Care Med*. 153:317-324

Pfyffer, G.E., 2000. Drug-resistant tuberculosis: resistance mechanism and rapid susceptibility testing. *Schweiz Med Wochenschr*. (130)1909-1915.

- Rubenstein, D., 2005. *Kedokteran Klinis*. Erlangga, Jakarta.
- Ryan, K.J., Ray, C.G., Ahmad, N., Drew, W.L., Plorde, J.J., 2010. *Sherris Medical Microbiology*. 5th ed. Mc Graw Hill Medical.
- Seddon, J.A., Hesselning, A.C., Willemse, M., Donald, P.R., Schaaf, H.S. 2011. Culture-Confirmed Multidrug-Resistant Tuberculosis in Children: Clinical Features, Treatment, and Outcome. *Clinical Infectious Diseases*. 54(2):157-66
- Smith, T., Wolff, K.A., Nguyen, L. 2013. Molecular Biology of Drug Resistance in Mycobacterium tuberculosis. *Curr Top Microbiol Immunol*. 374: 53-80.
- Spicer, W.J., 2008. *Clinical microbiology and infectious diseases*. Ed 2. Churchill Livingstone, New York.
- Weiss, P., Chen, W., Cook, V.J., Johnston, J.C. 2014. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. *BMC Infectious Diseases*. 14:333
- WHO. 2011. *The Global Plan To Stop TB 2011-2015*. WHO, Switzerland.
- WHO. 2014. *Companion Handbook to The WHO Guidelines for The Programmatic Management of Drug-Resistant Tuberculosis*. WHO, Switzerland.
- Willey, J.M., Sherwood, L.M., Woolverton, C.J., 2009. *Prescott's Principles of Microbiology*. McGraw-Hill, New York.